• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sarepta Therapeutics (NQ: SRPT )

    147.64 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 45
    Open 147.64
    Bid (Size) 145.01 (1)
    Ask (Size) 149.87 (1)
    Prev. Close 147.64
    Today's Range 147.64 - 147.64
    52wk Range 55.25 - 173.25
    Shares Outstanding 93,148,652
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
    Via Benzinga
    SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.
    The CEO of Cassava Sciences is stepping down, effective immediately. Here's what this means for troubled SAVA stock. 
    Via InvestorPlace

    Performance

    YTD
    +53.46%
    +53.46%
    1 Month
    -9.89%
    -9.89%
    3 Month
    +26.06%
    +26.06%
    6 Month
    +21.89%
    +21.89%
    1 Year
    +41.30%
    +41.30%

    More News

    Read More
    Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
    Via Benzinga
    Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
    From Cassava Sciences, Inc.
    Via GlobeNewswire
    Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
    Via Benzinga
    Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 Analysts
    Via Benzinga
    Looking At Sarepta Therapeutics's Recent Unusual Options Activity
    Via Benzinga
    After a Big Win, Is Sarepta Therapeutics Stock a Buy?
    Via The Motley Fool
    Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
    Via The Motley Fool
    Exposures Product Safety
    1 Soaring Growth Stock to Buy and Hold for 10 Years
    Via The Motley Fool
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
    Via The Motley Fool
    Here's How Much You Would Have Made Owning Sarepta Therapeutics Stock In The Last 10 Years
    Via Benzinga
    Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
    Via Investor's Business Daily
    Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio?
    Via Benzinga
    Google Parent Alphabet At All-Time High, In Stock Spotlight: See New Names On IBD 50, Stock Spotlight And More
    Via Investor's Business Daily
    Growth Stocks Leave Value Stocks In The Dust: 4 Reasons For Biggest Monthly Lead In Over A Year
    Via Benzinga
    Nasdaq Moves Lower; FactSet Research Posts Upbeat Earnings
    Via Benzinga
    Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
    Via Benzinga
    Stocks Stall As Chip Sector Struggles To Rebound; Dollar Eyes 7-Week Peak, Gold, Bitcoin Retreat: What's Driving Markets Friday?
    Via Benzinga
    Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says
    Via Benzinga
    Exposures Product Safety
    Gold Down 1%; CarMax Shares Gain After Q1 Earnings
    Via Benzinga
    Sarepta Therapeutics Stock Soars on FDA Approval
    Via MarketBeat
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.